TY - JOUR
T1 - Visualization and characterization of cancer stem-like cells in cervical cancer
AU - Hayashi, Kazuhiko
AU - Tamari, Keisuke
AU - Ishii, Hideshi
AU - Konno, Masamitsu
AU - Nishida, Naohiro
AU - Kawamoto, Koichi
AU - Koseki, Jun
AU - Fukusumi, Takahito
AU - Kano, Yoshihiro
AU - Nishikawa, Shlmpei
AU - Miyo, Masaaki
AU - Noguchi, Kozo
AU - Ogawa, Hisataka
AU - Hamabe, Atsushl
AU - Seo, Yuji
AU - Doki, Yuichlro
AU - Mori, Masaki
AU - Ogawa, Kazuhiko
PY - 2014
Y1 - 2014
N2 - Cancer stem cells (CSCs), defined by their differentiation capacity, self-renewal capacity, and maintenance of proliferation, have been identified in many tumors, including cervical cancer. Current studies identify CSCs by several specific biomarkers; however, it is difficult to monitor cervical CSCs in real-time in vitro and in vivo. Recent research reported the visualization of CSCs in breast cancer and gliomas using green fluorescent protein, ZsGreen, fused to a degron motif ornithine decarboxylase (ODC), which is destroyed by proteasomes. Accordingly, CSCs have low 26S proteasome activity, whereas non-CSCs have high 26S proteasome activity. Therefore, it is possible to observe CSCs by their accumulation of the fluorescent ZsGreen protein. In this study, we investigated optical imaging parameters to evaluate CSCs using two human cervical cancer cell lines: CaSki and HeLa. We defined populations as cell types having high- and low ZsGreen-cODC (high- and low-Zs, respectively) expression levels. The results of a sphere-forming assay revealed that the self-renewal ability of the high-Zs population was significantly higher than that of the low-Zs population. A tumorigenicity assay confirmed that the high-Zs population exhibited higher tumorigenic potential than the low-Zs population. The radioresistance of the high-Zs population of both HeLa and CaSki cells and the chemoresistance of the high-Zs population of CaSki cells were confirmed by a clonogenic survival assay and the tetrazolium dye assay, respectively. These results indicate that high-Zs populations of both the HeLa and CaSki cell lines possess CSC-like properties and therapeutic resistance. In conclusion, we successfully visualized CSC-like cells using a fluorescent protein system.
AB - Cancer stem cells (CSCs), defined by their differentiation capacity, self-renewal capacity, and maintenance of proliferation, have been identified in many tumors, including cervical cancer. Current studies identify CSCs by several specific biomarkers; however, it is difficult to monitor cervical CSCs in real-time in vitro and in vivo. Recent research reported the visualization of CSCs in breast cancer and gliomas using green fluorescent protein, ZsGreen, fused to a degron motif ornithine decarboxylase (ODC), which is destroyed by proteasomes. Accordingly, CSCs have low 26S proteasome activity, whereas non-CSCs have high 26S proteasome activity. Therefore, it is possible to observe CSCs by their accumulation of the fluorescent ZsGreen protein. In this study, we investigated optical imaging parameters to evaluate CSCs using two human cervical cancer cell lines: CaSki and HeLa. We defined populations as cell types having high- and low ZsGreen-cODC (high- and low-Zs, respectively) expression levels. The results of a sphere-forming assay revealed that the self-renewal ability of the high-Zs population was significantly higher than that of the low-Zs population. A tumorigenicity assay confirmed that the high-Zs population exhibited higher tumorigenic potential than the low-Zs population. The radioresistance of the high-Zs population of both HeLa and CaSki cells and the chemoresistance of the high-Zs population of CaSki cells were confirmed by a clonogenic survival assay and the tetrazolium dye assay, respectively. These results indicate that high-Zs populations of both the HeLa and CaSki cell lines possess CSC-like properties and therapeutic resistance. In conclusion, we successfully visualized CSC-like cells using a fluorescent protein system.
UR - http://www.scopus.com/inward/record.url?scp=84907688067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907688067&partnerID=8YFLogxK
U2 - 10.3892/ijo.2014.2670
DO - 10.3892/ijo.2014.2670
M3 - Article
C2 - 25269542
AN - SCOPUS:84907688067
SN - 1019-6439
VL - 45
SP - 2468
EP - 2474
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 6
ER -